- A +

Gene Therapy Against Blindness

We are a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, we leverage our integrated development platform by combining a gene therapy-based approach with our core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics.

Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative ophthalmology companies.

Our initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.

 

2015 Next events

15June2015

BIO, June 15-17, Philadelphia (PA)

BIO, June 15-18, Philadelphia (PA)

21June2015

21-24 June, 2015 GenSight will attend EUNOS,

GenSight will attend EUNOS, 13th congress of European Society for Neuroophthalmology, in Ljubljana, Slovenia. Oral presentation on the intravitreal injection of rAAV2/2-ND4, a recombinant adeno-associated viral vector serotype 2 (rAAV2/2); poster onLeber’s Hereditary Optic Neuropathy (LHON).

Other events View all events

April 22-24, 2015: GenSight will present at the World Orphan Drug Congress.

March 12, 2015: GenSight participated at the 5th Annual Advanced Therapies Summit.

 January 7, 2015

SIGHT AGAIN

GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total €18.5 million funding for SIGHT AGAIN as part of the Investment for the Future. This public - private project with an overall budget of € 47 million aims to restore vision to legally blind patients with retinitis pigmentosa at different stages of the disease.

Other news

06 May 2014

Jean-Philippe Combal as Chief Operating Officer

GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

08 April 2013

GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy

Paris, France, April 8th, 2013 – GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a €32 million Series A financing.

Read all news

Discover our videos